Key result
Dicumarol therapy for acute myocardial infarction may not be as successful under average hospital practice conditions as it is in highly supervised research settings.
Why the study?
Does Dicumarol reduce mortality and thromboembolic complications in patients with acute myocardial infarction?
Observational
Does Dicumarol reduce mortality and thromboembolic complications in patients with acute myocardial infarction?
The study aims to evaluate the real-world effectiveness of Dicumarol therapy for acute myocardial infarction in average hospital practice, as opposed to strictly controlled research settings.
Answers are grounded in this paper and cite their sources.
May limit Dicumarol use in routine acute MI care; challenges generalizability of benefits seen in supervised trials.
NUMEROUS reports1 2 3 4 5 6 during the past few years have emphasized the value of Dicumarol therapy in reducing the mortality rate and the incidence of thromboembolic complications following acute myocardial infarction. These series have in general represented carefully followed cases under the direct supervision of well organized research teams, and results as reported have been favorable. Consequently, the statement has been made that Dicumarol therapy is indicated in every case of myocardial infarction in which proper laboratory facilities are available.However, modes of therapy that work well under research conditions may not be so successful under the conditions of average hospital practice. . . .
No takes yet. Share an insight, caveat, or question.
Bresnick et al. (1950) conducted an observational in Acute Myocardial Infarction. Dicumarol was evaluated on Mortality rate and thromboembolic complications. Dicumarol therapy for acute myocardial infarction may not be as successful under average hospital practice conditions as it is in highly supervised research settings.
Synapse has enriched 10 related papers. Consider them for comparative context: